Summary
Introduction
Multiple sclerosis (MS) is an autoimmune disorder characterized by central nervous system (CNS) damage. Approximately 85% of patients with MS suffer from a relapsing-remitting form of MS. 1 Relapsing-remitting MS is associated with unpredictable, self-limiting bouts of CNS dysfunction, which vary in their frequency and duration. MS is a complex disease with an equally complex pathophysiology, as indicated by the heterogeneity in the level of clinical presentations as well as morphological differences in brain lesions. 2 Multiple sclerosis is characterized by a profound inflammatory cell infiltrate into the CNS. The migration of inflammatory T cells to the CNS is critical to the development of MS and mice deficient in CD4 or CD8 T cells exhibit a reduced incidence of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. 3 Recruitment of inflammatory cells into the CNS requires cells to cross the blood-brain barrier, with its breakdown being one of the initial steps in the development of MS. Chemokine and chemokine receptor expression is critical for inflammatory cell migration, recruitment to the CNS and subsequent disease pathology. 4 The chemokine receptors CCR2 and CCR7 are of particular importance in MS and EAE. CCR2
À/À mice are resistant to EAE, 5 CCR2 expression is observed on CNSinfiltrating dendritic cells (DCs) 6 and elevated levels of CCR2 have been found in CNS tissue of patients with MS. 7 It is well established that CCR7 is required for lymphocyte retention in lymphoid tissues such as lymph nodes (LNs) and several reports suggest the importance of CCR7 expression on lymphocytes in EAE 8 and in MS 9 for CNS recruitment. Both T helper type 1 (Th1) and Th17 cells are posited to be pathogenic/pro-inflammatory CD4 + T-cell subsets in MS. 10 Dendritic cells facilitate recruitment of T cells into the CNS, 11 and are critical antigen-presenting cells in EAE, driving the Th17 lineage. 12 The DCs secrete interleukin-12 (IL-12), associated with Th1 lineage commitment, and transforming growth factor-b and IL-6, associated with Th17 polarization. 10 In MS, DCs are abundant in brain lesions and, together with microglia, function to reactivate CD4 + T cells as they enter the CNS, driving myelin-specific Th17/Th1 polarization associated with neuroinflammation, demyelination and neuronal damage. A predominant role for DCs in the pathogenesis of MS is underscored by the association of specific HLA class II molecules accounting for 10-60% of the genetic risk linked to MS. 13 Dendritic cells are sufficient to induce autoimmunity in the CNS; 14 increasing their numbers exacerbates EAE, 15 and their depletion ablates the induction of EAE. 6 By contrast, some reports have suggested a tolerogenic role for DCs in the context of T-cell priming and activation in EAE. 16, 17 Viewed together, these findings highlight the importance of DCs in CNS autoimmunity.
Interferon-b (IFN-b) remains one of the first-line treatments for patients with relapsing-remitting MS. Treatment with IFN has shown benefits in outcome measures related to relapses, progression of disability and magnetic resonance imaging. It exhibits pleiotropic effects in MS, including modulation of adhesion molecule expression, inhibition of matrix metalloproteinase activity and regulation of leucocyte trafficking. 18 In EAE, IFN-b reduces relapse rates and leads to improvements in clinical scores. 19 Mice that are IFN-b À/À have been used in EAE studies to validate the importance of IFN-b treatment in limiting the pathogenesis of the disease 20, 21 and in relapsing-remitting EAE, where there was evidence of increased frequency of relapses. 20 We and others have shown regulatory roles for IFN-b in Th17 cell polarization. 22, 23 Treatment with IFN-b decreases IL-17 gene and protein expression in proliferating murine CD4 + cells and prevents the elevation of IL-17 mRNA in cells from the CNS draining LNs. 24 In this report we describe a role for IFNb in regulating the DC immunophenotype, affecting DC effects on T-cell activation, Th17 lineage polarization and DC migration in EAE.
Materials and methods

Mice
The IFN-b +/+ and IFN-b À/À mice 25 were bred and maintained in a specific pathogen-free colony in accordance with guidelines set by University Health Network's Animal Care committee. Mice were genotyped by PCR as previously described.
21 C57BL/6-Tg (Tcra2D2,Tcrb2D2) Kuch1/J (2D2) transgenic mice with T-cell receptor specificity for myelin oligodendrocyte glycoprotein (MOG) 35-55 were purchased from the Jackson Laboratory (Bar Harbor, ME) and bred with wild-type C57BL/6 mice in our colony to obtain mice heterozygous for the 2D2 transgene. Mice were genotyped by flow cytometry as previously described.
26
Bone-marrow-derived DC generation
Bone-marrow-derived dendritic cells (BMDCs) were generated as reported previously. 27 Briefly, IFN-b +/+ and IFN-b À/À mice aged 6-12 weeks were killed, their femurs were harvested and flushed, and the resulting cells were passed through a 70-lM filter. Progenitors were plated at 2 9 10 6 cells per plate in bacterial Petri dishes. Cells were cultured for 9 days in RPMI-1640 medium supplemented with 10% fetal calf serum, 100 U penicillin and streptomycin, 2 mM L-glutamine, 20 lM b-mercaptoethanol (complete RPMI). Recombinant mouse granulocytemacrophage colony-stimulating factor (Peprotech, Rocky Hill, NJ) was added on days 0, 3, 6 and 8 at 40 ng/ml. On day 9, cells in suspension were aspirated, washed, counted and seeded at a density of 2 9 10 6 /well in 24-well tissue-culture plates. BMDCs were matured by adding 1 lg/ml of lipopolysaccharide (LPS) (Escherichia coli, O55:B5; Sigma-Aldrich, Oakville, ON, Canada) for 16 hr. When BMDCs were primed with MOG 35-55 peptide (McGill Sheldon Biotechnology Centre, Montreal, QC, Canada), it was at a concentration of 1 lg/ml for 2-3 hr on day 10 of DC culture. The LPS-activated (or LPS-activated, MOG-primed) BMDCs were then washed three times with complete RPMI before use.
Dendritic cell isolation and activation
The IFN-b +/+ or IFN-b À/À mice, 6-8 weeks of age, were killed, and their spleens or inguinal LNs were harvested and digested with 1 lg/ml collagenase A (Roche Life Science, Oakville, ON, Canada) and 0Á1 lg/ml DNase I (Roche) in PBS for 30 min at 37°. The reaction was stopped by incubating with 1 mM EDTA for 10 min at room temperature. Cell suspensions were subsequently passed through a 70-lM filter and contaminating red blood cells were lysed by incubating in red blood cell lysis buffer (150 mM NH 4 Cl, 10 mM KHCO 3 , 0Á1 mM Na 2 EDTA), for 5 min on ice. Cells were washed, resuspended in PBS and counted, then, as indicated, CD11c + cells were isolated by magnetic separation (Miltenyi Biotec, Auburn, CA) as per the manufacturer's instructions. In other studies, unfractionated splenocytes were plated at 2 9 10 6 cells per well in 24-well plates in complete RPMI medium. As indicated, CD11c + DCs were activated with 1 lg/ml LPS, then identified by antibody staining and FACS analysis.
CD4 + T-cell isolation and proliferation assays
Female 2D2 mice, 6-12 weeks of age, were killed, their spleens were harvested and CD4 + T cells were positively selected using a CD4 + selection kit (Miltenyi Biotec) as described previously. 22 The 
Fluorescence-associated cell sorting
Cells to be analysed for surface markers were washed and resuspended in FACS buffer (PBS with 2% fetal calf serum). Non-specific antibody binding was blocked using 10% mouse serum in FACS buffer for 10 min at room temperature. The following antibodies were used (all antibodies were from BioLegend, San Diego, CA, unless otherwise indicated): anti-CD4-BV650, anti-CD3-BV510, anti-MHCII (I A /I E )-FITC (eBioscience) or -BV650, anti-CCR7-phycoerythrin (eBioscience), anti-CD80-phycoerythrin-Cy5 or -phycoerythrin (eBioscience), anti-CD86-FITC or -allophycocyanin, anti-CD11c-AlexaFluor 700, anti-CD11b-BV421, anti-B220-BV711 and anti-CCR2-AlexaFluor 647. Cells were stained for 30 min at 4°and then washed three times with FACS buffer. Cells were analysed using a Beckton Dickinson LSRII flow cytometer and appropriate isotype controls, and fluorescence minus one controls were used in each experiment to gauge nonspecific staining and to determine gates. Flow cytometry files were analysed using FLOWJO software (FlowJo, Ashland, OR).
Cytokine analysis (FlowCytomix and ELISA)
Supernatants from cell cultures were stored at À80°. 
Gene expression analysis
The BMDCs were generated from female IFN-b +/+ (n = 3) and IFN-b À/À (n = 3) mice as described above and either left untreated or treated with LPS (1 lg/ml) for 6 hr. Pooled BMDCs were then washed and RNA was extracted using the RNeasy isolation kit according to the manufacturer's instructions (Qiagen, Toronto, ON, Canada). RNA was then submitted to the UHN Microarray Facility, where 200 ng/sample was hybridized to the Illumina mouse whole genome WG-6 v2 BeadChip, as per standard protocols. The WG-6 v2 BeadChip contains probes for > 42 500 transcripts spanning the mouse genome, and includes probes identified from the NCBI RefSeq database, the mouse exonic evidence based oligonucleotide (MEEBO) probe set and protein coding sequences from the RIKEN FANTOM2 database. Data were analysed using Illumina's GENOMESTUDIO software. Raw fluorescence intensities were background corrected and the resulting probe fluorescence intensities from LPSstimulated samples were compared with the untreated control for each mouse genotype. Fold change was calculated from the log2-transformed data.
EAE and adoptive transfer experiments
Experimental autoimmune encephalomyelitis was induced in IFN-b +/+ and IFN-b À/À mice as previously described. 21 Briefly, a subcutaneous injection of 50 lg of MOG peptide mixed with complete Freund's adjuvant (10 mg/ml Mycobacterium tuberculosis; Sigma Aldrich) was administered in the hind flank of mice on day 0, and 400 ng of pertussis toxin was given by intraperitoneal injection on days 0 and +2 relative to MOG. Disease progression was scored using a five-point ascending scale: 0 = no signs of disease, 1 = limp tail, 2 = hind limb weakness, 3 = partial hind limb paralysis, 4 = full hind limb paralysis, 5 = moribund. For DC isolation and co-culture with 2D2 CD4 + T cells, DCs were isolated from mice on day 3 of EAE, from the injection site draining LN, and CD11c mice on day 3 of EAE via the tail vein. Twenty-four and 72 hr following injection, mice were killed, and their spleens, spinal cords and brains were removed and fixed in 10% formalin. After 24 hr, tissues were transferred into PBS, and imaged using a Xenogen IVIS (Xenogen, Caliper Life Science, Waltham, MA). The excitation was set at 640 nm and the emission filter used was 680 nm.
Results
Interferon-b influences DC cytokine production
Our earlier studies identified that IFN-b À/À mice are more susceptible to EAE than IFN-b +/+ mice. 21 Given that in MS DCs drive the Th1/Th17 T-cell polarization associated with neuroinflammation, we undertook a series of experiments to determine whether the absence of IFN-b might influence cytokine production by DCs, thereby affecting T-cell polarization. Accordingly, we generated BMDCs from IFN-b +/+ and IFN-b À/À mice in vitro and stimulated these DCs with the Toll-like receptor-4 agonist, LPS, for 16 hr. Culture supernatants from these stimulated BMDCs were analysed for Th1/ Th2/Th17/Th22 cytokines. Our data reveal increased IL-6 and IL-23 ( 
Interferon-b modulates co-stimulatory molecule expression on DCs
As we have consistently observed a discriminating capacity for IFN-b À/À CD11c + DCs to enhance T-cell proliferation, we investigated whether this might be a direct mice and DCs were generated in vitro using granulocyte-macrophage colony-stimulating factor (40 ng/ml). After 10 days in culture, DCs were harvested, stimulated with lipopolysaccharide (LPS) (1 lg/ml) for 16 hr, and the culture supernatants were assessed for cytokines by multiplex cytokine analysis or ELISA. Data for (a) interleukin-6 (IL-6), (b) IL-23, (c) tumour necrosis factor-a (TNF-a, (d) IL12p40, (e) IL-27, (f) IL-10 and (g) interferon-b (IFN-b) are shown. UD = cytokine undetectable. Values are means AE SE. Significant differences were determined by Student's t-test. *P < 0Á05, **P < 0Á01, ***P < 0Á001, ****P < 0Á0001. Data are representative of two independent experiments with three mice per group. Quantification of replicate samples of CD4 + T cells are shown. Horizontal bars denote means AE SE. Significant differences were measured using Student's t-test. **P < 0Á01. Data are representative of two independent experiments with four mice per group (three technical replicates per mouse).
CD11c
+ DCs expressing CD86 constitutively (5Á4%), compared with IFN-b À/À CD11c + DCs (4Á1%) (Fig. 3b) . As anticipated, LPS treatment led to DC activation, indicated by increased percentages of CD80 + and CD86 + expressing CD11c + DCs, and increased MHCII expression (Fig. 3c) (Fig. 3a) . We observed a modest, yet significant increase in the percentage of CD86-expressing DCs when derived from IFNb +/+ mice (43Á8%) compared with IFN-b À/À mice (35Á5%), after LPS stimulation (Fig. 3b) (Fig. 3c) . Furthermore, LPS stimulation significantly increased MHCII expression to a greater extent on the IFN-b À/À DCs compared with the IFNb +/+ DCs (Fig. 3c) .
DCs from IFN-b À/À mice with EAE induce enhanced MOG-transgenic CD4 + T-cell proliferation and drive Th17 polarization ex vivo Activation of DCs using LPS may differ from activation of DCs in the context of EAE induction, as Toll-like receptor agonists are known potent activators of DCs. 
Interferon-b modulates CCR7 expression on DCs influencing their migratory capacity
Dendritic cells that express CCR7 respond to gradients of CCL19 and CCL21, directing them to the T-cell zones of lymphoid organs where they interact with and activate naive T cells. Moreover, DCs in CNS lesions have been shown to express CCR7. 13 CCR2 expression has been extensively studied in EAE, with data indicating that CCR2 À/À mice have fewer CNS-infiltrating T cells and macrophages. Significant differences were measured by the Mann-Whitney U-test. *P < 0Á05, **P < 0Á01, ***P < 0Á001, and ****P < 0Á0001. Data are representative of at least three independent experiments with three mice per group and three technical replicates per mouse. was also increased to a greater level after LPS stimulation (Fig. 6a) . Furthermore, we provide evidence that CCR7 expression is increased on DCs from the spleens and draining LNs of IFN-b À/À mice with EAE (Fig. 6b) mice, yet had no effect on STAT1 gene expression in BMDCs from IFN-b À/À mice (Fig. 6c) .
In a final series of experiments we examined the effects IFN-b on DC migration to the CNS in the context of EAE. In vitro generated BMDCs, derived from IFN-b (Fig. 6d) . Notably, at 24 and 72 hr post-infusion, none of these mice displayed any symptoms of EAE. At both 24 and 72 hr post-infusion we observed a greater accumulation of DCs in the brains of 
Discussion
Dendritic cells represent an important component of the immune system, bridging the innate and adaptive immune responses: detecting and presenting antigens to T cells to induce an appropriate immune response and generate subsequent immunological memory. DCs may also present self-antigens to T cells, effecting a breakdown in tolerance, leading to autoimmunity and detrimental immune responses against tissues and organs. As such, identifying the specific effects of disease-modifying treatments in MS on DCs is important, as there is evidence that modifying DC function influences disease progression in EAE. 6, 11, 14 As IFN-b therapy remains an important treatment for MS, the molecular mechanisms involved in its beneficial effects related to DCs were the subject of these studies. Patients with MS have higher levels of pro-inflammatory cytokines in their serum and blood. 33, 34 Treatment with IFN-b alters cytokine profiles in EAE and in patients with MS, increasing regulatory or anti-inflammatory cytokines, 35 and decreasing pro-inflammatory cytokines. 36 DCs secrete pro-and anti-inflammatory cytokines in MS and EAE, which guide T-cell differentiation. Interleukin-27 has been implicated in regulating Th17 responses in murine EAE experiments and in human CD4 + T cells. 37, 38 There is evidence that IFN-b treatment of both mouse and human DCs in vitro leads to production of both IL-27 and IL-10. 35, 36, 39 Additionally, DCs generated from patients with MS that respond to IFN-b therapy produce more IL-27 in response to IFN-b treatment, compared with non-responders. 35 In agreement, we identified that Fig. 1 ). These data are supportive of a role for IFN-b regulating DC production of cytokines that affect CD4 + T-cell polarization. These results align with our previous findings of increased CD4 + IL-17A + T cells in IFN-b À/À mice, associated with exacerbated EAE. 31, 32 We infer that in the presence of IFN-b, activated DCs will limit CD4 + T-cell polarization to pathogenic Th17 cells, thereby contributing to less severe EAE or MS.
A number of reports have indicated a role for IFN-b in limiting IL-17 production in MS and EAE, [22] [23] [24] 36 however, recent work by Axtell and others indicated that IFN-b could exacerbate Th17-induced EAE. 41 Herein we provide evidence that the absence of IFN-b in DCs led to induction of pro-inflammatory cytokines IL-6, IL-23, IL-17 and IFN-c when cultured with 2D2 transgenic CD4 + T 3500 (a) 26 Notably, the DCs isolated from EAE mice were harvested on day 3 after disease induction, so we infer that it is unlikely that within this time period naive CD4 + T cells had been sufficiently activated and polarized to secrete cytokines that would, in turn, target these DCs in vivo. Taken together with our data indicating a role for IFN-b in regulating expression of MHCII and CD80 on DCs, we postulate that IFN-b may be required in DCs to limit interactions with CD4 + T cells that lead to their activation and polarization to the Th17 lineage.
One of the proposed mechanisms of IFN-b action in MS is to regulate cell proliferation. In our earlier work, we provide evidence that IFN-b À/À splenocytes are hyperproliferative in response to non-specific stimuli. 25 Interferon-b exerts antiproliferative effects when added to peripheral blood monocyte cultures from patients with MS, inhibiting the proliferation of both CD4 + and CD8 + T cells. 42 Given these inhibitory effects of IFN-b on T-cell proliferation, we postulated that IFN-b may regulate the DC contribution to proliferation of T cells, herein supported by our data that DCs from IFN-b À/À mice induce a greater proliferation of CD4 + T cells than DCs derived from IFN-b +/+ mice (Fig. 2) . Circulating DCs in patients with MS have elevated levels of co-stimulatory markers when compared with healthy controls, 43 and patients with MS have more activated conventional DCs in their cerebrospinal fluid compared with their blood. 44 Antigen-presenting cells in the CNS have been implicated in re-activation of T cells during EAE. Teige et al. provided evidence that IFN-b downregulates the antigen-presenting capacity of CNS glial cells, thereby potentially resulting in less efficient activation of autoreactive T cells in EAE. 45 In (Fig. 4 and data not shown). Interestingly, plasmacytoid DCs from patients with MS treated with IFN-b exhibit decreased expression of MHCII and CD86. 46 Patients with MS that does not respond to IFN-b treatment have increased expression of CD86 on their myeloid DCs, compared with patients whose MS responds to IFN-b therapy. 47 Given that IFN-b therapy is only effective in about 30% of patients with MS, the variable response to IFN-b therapy may reflect the variable responsiveness of different DC populations to IFN-b, the subject of our ongoing investigations.
Migration of DCs to the CNS, orchestrated by chemokines that interact with CCR2 and CCR7, is critical for re-activating T cells during EAE. 6, 13, 14 Although we did identify an increase in CCR2 expression on BMDCs in response to LPS treatment, this was IFN-b-independent. Studies have identified the importance of the CCR7 ligands CCL19 and CCL21 for maintaining an inflammatory state in the CNS during EAE, 8, 48 and there is evidence for CCR7 + cells accumulating in the CNS during MS.
9, 49 We previously showed that LPS-stimulated IFNb À/À bone-marrow-derived macrophages had lower STAT1 gene expression and were deficient in their ability to phosphorylate STAT1 compared with their IFN-b +/+ counterparts. 31 In other studies it has been shown that treatment of IFN-b À/À macrophages with IFN-b will induce STAT1 phosphorylation and restore IFN-b-inducible gene expression. 32 Another study identified that IFNb treatment inhibited DC migration, through STAT1 transcriptional inhibition of CCR7. 29 In our present study we provide evidence that IFN-b À/À BMDCs are unable to induce STAT1 gene expression upon LPS stimulation, and although we did not analyse STAT1 phosphorylation in response to LPS treatment, given the findings of Sheikh et al. 32 that LPS is unable to induce activation of STAT1 in IFN-b À/À macrophages, we assume that a failure of STAT1 phosphorylation would also be observed in IFN-b À/À BMDCs. We provide evidence that IFN-b
BMDCs have increased surface expression of CCR7 when compared with IFN-b +/+ BMDCs, whether naive (unstimulated) or in response to LPS stimulation. On day 9 after EAE induction, we observed a modest trend of increased CCR7 expression on DCs from the spleens and LNs of IFN-b À/À mice compared with their IFN-b +/+ counterparts, albeit not statistically significant (Fig. 6b) . These findings are in agreement with the IFN-b inhibition of CCR7 mediated by STAT1, described by Yen et al., 29 suggestive of a role for endogenous IFN-b in the regulation of CCR7. Although CCR7 À/À mice are not protected from EAE and develop disease comparable to CCR7
+/+ mice, T-cell responses appear to be initiated in the spleen, rather than the LNs of these mice. Of note, the Yen study did not address the migration of DCs or T cells to the CNS during disease, which may be altered in the absence of CCR7. 50 Even though CCR7 does not appear to be necessary for induction of EAE, the findings that IFN-b can inhibit its expression, in part by regulation of STAT1, suggest a role for IFN-b in regulating cell migration in EAE. In our BMDC adoptive transfer experiment, we provide evidence that BMDCs generated from IFN-b À/À mice rapidly migrate to the CNS of mice primed for EAE, in the absence of clinical scores. Our findings support the notion that one of the immunoregulatory roles of IFN-b during neuroinflammation is to limit DC migration, in part mediated through STAT1 transcriptional inhibition of CCR7.
Taken together, our data highlight an important role for IFN-b in regulating the interactions of T cells and DCs in the context of EAE. We show that IFN-b is required to modulate the function of DCs in terms of antigen presentation and co-stimulation of T cells, and regulates DC cytokine production that determines T-cell lineage commitment. We point to a role for IFN-b in regulating migration of DCs into lymphoid tissues and the CNS during EAE. Our findings of immunoregulatory properties of IFN-b in DCs in the context of EAE provide further support for consideration of DC-targeted therapies in MS.
